Physician profile
Ramesh Singa
NPI 1184981805
$34,126.26
in general payments reported to CMS, 2019-2025
55 companies · $3,625 in 2025
The $3,625 reported for 2025 was more than what 91% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,905 · 2020: $5,149 · 2021: $5,338 · 2022: $5,776 · 2023: $5,934 · 2024: $5,399 · 2025: $3,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Travel and Lodging: $665 · Consulting Fee: $600 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,292.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Travel and Lodging | $665.44 |
| Consulting Fee | $600.00 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,125.82 | 2019-2025 | Proclaim, Eterna, Octrode |
| Scilex Pharmaceuticals INC. | $4,564.04 | 2019-2023 | Ztlido |
| Omnia Medical, LLC | $3,150.00 | 2020 | |
| Relievant Medsystems, INC. | $2,318.89 | 2021-2023 | Intracept |
| Boston Scientific Corporation | $1,973.58 | 2019-2025 | Intracept |
| Medtronic Vascular, INC. | $1,550.42 | 2019-2020 | |
| Protega Pharmaceutials INC | $1,094.36 | 2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $964.63 | 2019-2025 | Belbuca, Xtampza |
| Spinal Simplicity, LLC | $949.44 | 2022-2025 | Ha Minuteman G3-R |
| Ibsa Pharma INC. | $883.28 | 2021-2024 | Licart, Tirosint, Licart |
| Medtronic, INC. | $673.47 | 2022-2024 | Intellis Adaptivestim, Ascenda, Synchromedii |
| Si-Bone, INC. | $656.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $609.24 | 2020-2025 | Relistor, Trulance |
| Lilly USA, LLC | $549.08 | 2019-2022 | |
| Abbvie INC. | $540.77 | 2021-2024 | Ubrelvy, Qulipta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Singa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.